Page 10 - Layout 1

Strength of Evidence Insufficient Low Insufficient Insufficient Insufficient Insufficient Low Low Low Low Low Insufficient Insufficient

Effect Estimate N/A OR = 0.09 (0.01, 0.70) OR = 1.00 (0.02, 50.75) N/A OR = 0.30 (0.02, 5.85) N/A OR = 0.47 (0.33, 0.68) OR = 0.52 (0.35, 0.76) OR = 0.20-0.29 (lower CI range 0.07-0.16, upper CI range 0.52-0.61)†† OR = 0.21 (0.09, 0.50) OR = 0.04 (0.00, 0.65) N/A OR = 0.72-0.75 (lower CI range 0.47-0.58, upper CI

Comparator N/A Oral tocolytics Oral nifedipine N/A No treatment N/A Oral nifedipine Oral tocolytics Oral nifedipine Oral tocolytics No treatment N/A Oral nifedipine

for populations of interest Table B. SQ terbutaline pump versus comparator: Strength of evidence Population of Total Number Interest of Events N/A N/A Twin gestation 12 + RPTL Singleton gestation 0 + RPTL N/A N/A Singleton gestation 4 + RPTL N/A N/A Twin gestation 192 + RPTL Twin gestation 124 + RPTL Singleton gestation 106 + RPTL Singleton gestation 37 + RPTL Singleton gestation 21 + RPTL N/A N/A Singleton gestation 925 +

Number of Participants 0 706 284 0 60 0 656 706 1650 558 60 0 1650

Number of Studies 0 1 19 1 17 0 113 0 1 16 1 19 2 15,17 1 18 1 13 0 2 15,17

Outcome Neonatal Health Outcomes (KQ1): BPD Neonatal Health Outcomes (KQ1): Neonatal death* Neonatal Health Outcomes (KQ1): Death within initial hospitalization Neonatal Health Outcomes (KQ1): Significant IVH (Grade III/IV)† Other Surrogate Outcomes (KQ2): Incidence of delivery < 28 weeks Other Surrogate Outcomes (KQ2): Incidence of delivery < 32 weeks Other Surrogate Outcomes (KQ2): Incidence of delivery < 34 weeks‡ Other Surrogate Outcomes

10